Activin RIIB Antibody (bimagrumab) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28282F
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # bimagrumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Activin RIIB Antibody (bimagrumab) [FITC]
Immunogen
ACVR2B
Reactivity Notes
Predicted species reactivity: Mouse, Rat, Cynomolgus
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for Activin RIIB Antibody (bimagrumab) [FITC]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Activin RIIB
Long Name
Activin Receptor IIB
Alternate Names
ActivinRIIB, ACVR2B
Gene Symbol
ACVR2B
Additional Activin RIIB Products
Product Documents for Activin RIIB Antibody (bimagrumab) [FITC]
Product Specific Notices for Activin RIIB Antibody (bimagrumab) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...